Introduction

Peptide formulation excipients are inactive ingredients added to peptide drug products to ensure stability, isotonicity, and acceptable delivery characteristics. The selection of excipients is critical for maintaining peptide integrity, preventing aggregation, and ensuring patient safety. This article covers the major excipient classes, their mechanisms of action, and compatibility considerations for peptide formulations.

Buffer Systems

Purpose

Buffers maintain the pH of peptide formulations within a narrow range to:

• Prevent acid/base-catalyzed degradation
• Maintain conformational stability
• Ensure isotonicity
• Provide patient comfort at injection site

Common Buffer Systems

Buffer	pKa	Buffer Range	Notes
Acetate	4.76	3.76–5.76	Common for insulin
Citrate	3.13, 4.76, 6.40	2.5–6.0	Versatile, metal chelation
Phosphate	2.12, 7.21, 12.32	5.8–8.0	Physiological, but causes precipitation
Histidine	6.04	5.0–7.0	Excellent for biologics
Tris	8.06	7.0–9.0	Good buffering at pH 7–8

Buffer Selection Criteria

1. pH range:

• Most peptides: pH 4–7
• Acid-sensitive peptides: pH > 5
• Base-sensitive peptides: pH < 6

2. Buffer capacity:

• Sufficient to maintain pH during storage
• Typically 10–50 mM concentration
• Consider dilution upon administration

3. Compatibility:

• No reactive with peptide functional groups
• No catalysis of degradation pathways
• Compatible with container closure system

Buffer Compatibility with Peptides

Buffer	Compatibility	Notes
Acetate	Excellent	Non-reactive, volatile
Citrate	Good	May chelate metal ions
Phosphate	Moderate	May precipitate with Ca²⁺
Histidine	Excellent	Provides some antioxidant activity
Tris	Good	May degrade under oxidation

Tonicity Agents

Purpose

Tonicity agents adjust the osmolality of formulations to match physiological conditions (280–320 mOsm/kg):

• Prevent tissue damage at injection site
• Reduce pain
• Maintain isotonicity for cell-based products

Common Tonicity Agents

Agent	Osmolarity Contribution	Notes
NaCl	1.0 mOsm per mM	Most common
Mannitol	1.0 mOsm per mM	Non-ionic, stabilizing
Sucrose	1.0 mOsm per mM	Cryoprotectant
Glycerol	1.0 mOsm per mM	Viscosity modifier
Sorbitol	1.0 mOsm per mM	Non-ionic

Tonicity Calculation

For NaCl:

Tonicity (mOsm/kg) = 2 × [NaCl] × 1000 / MW_NaCl

For non-electrolytes:

Tonicity (mOsm/kg) = [Solute] × 1000 / MW_Solute

Example:

• 150 mM NaCl: 300 mOsm/kg (isotonic)
• 280 mM mannitol: 280 mOsm/kg (isotonic)

Tonicity Agent Selection

1. NaCl:

• Advantages: Physiological, well-characterized
• Disadvantages: May affect peptide stability (ionic strength)

2. Mannitol:

• Advantages: Non-ionic, stabilizing effect
• Disadvantages: More expensive than NaCl

3. Sucrose:

• Advantages: Stabilizing, cryoprotectant
• Disadvantages: May promote Maillard reaction

4. Sorbitol:

• Advantages: Non-ionic, low caloric value
• Disadvantages: May crystallize at high concentrations

Stabilizers

Antioxidants

1. Methionine:

• Mechanism: Scavenges free radicals
• Concentration: 0.01–0.1%
• Common in protein formulations

2. Ascorbic acid (Vitamin C):

• Mechanism: Reducing agent
• Concentration: 0.01–0.1%
• May reduce disulfide bonds

3. Butylated hydroxytoluene (BHT):

• Mechanism: Free radical scavenger
• Concentration: 0.001–0.01%
• Lipid-soluble antioxidant

4. Ethylenediaminetetraacetic acid (EDTA):

• Mechanism: Metal chelation
• Concentration: 0.01–0.05%
• Prevents metal-catalyzed oxidation

Surfactants

Purpose:

• Prevent aggregation
• Reduce surface tension
• Protect against interfacial stress

Common surfactants:

Surfactant	Type	Concentration	Notes
Polysorbate 20	Non-ionic	0.01–0.1%	Most common
Polysorbate 80	Non-ionic	0.01–0.1%	More hydrophobic
Poloxamer 188	Non-ionic	0.01–0.5%	Viscosity modifier
Poloxamer 407	Non-ionic	0.1–1.0%	Thermogelling

Cryoprotectants

Purpose:

• Protect during freezing and lyophilization
• Prevent ice crystal formation
• Maintain protein structure

Common cryoprotectants:

Agent	Mechanism	Concentration
Sucrose	Water replacement	5–10%
Trehalose	Water replacement	5–10%
Mannitol	Space filling	5–10%
Glycerol	Colligative effect	5–10%

Bulking Agents

Purpose:

• Provide cake structure during lyophilization
• Prevent collapse
• Improve reconstitution

Common bulking agents:

Agent	Concentration	Notes
Mannitol	2–5%	Most common
Sucrose	2–5%	Also cryoprotectant
Trehalose	2–5%	Also cryoprotectant
Glycine	1–3%	Good cake structure

Preservatives

Purpose

Preservatives prevent microbial growth in multi-dose formulations:

• Required for multi-dose vials
• Not needed for single-dose containers

Common Preservatives

Preservative	Concentration	Notes
Phenol	0.2–0.5%	Most common
m-Cresol	0.1–0.3%	Common with phenol
Benzyl alcohol	0.9–2.0%	Avoid in neonates
Benzalkonium chloride	0.004–0.02%	Cationic surfactant
Methylparaben	0.01–0.18%	Ester paraben

Preservative Compatibility

Factors affecting preservative efficacy:

1. Peptide concentration: High peptide may adsorb preservative
2. pH: Affects preservative ionization and activity
3. Temperature: Higher temperature reduces efficacy
4. Container closure: Rubber stoppers may absorb preservatives

Chelating Agents

Purpose

Chelating agents bind metal ions that catalyze degradation:

• Prevent metal-catalyzed oxidation
• Reduce aggregation
• Improve stability

Common Chelating Agents

Agent	Concentration	Notes
EDTA	0.01–0.05%	Most common
DTPA	0.001–0.01%	Stronger chelation
Citric acid	0.1–0.5%	Weak chelation
Tartaric acid	0.1–0.5%	Weak chelation

Viscosity Modifiers

Purpose

Adjust viscosity for:

• Ease of injection
• Sustained release
• Improved stability

Common Viscosity Modifiers

Agent	Type	Concentration	Notes
Glycerol	Low viscosity	1–5%	Common
Propylene glycol	Low viscosity	1–10%	Co-solvent
Carboxymethylcellulose	High viscosity	0.1–1%	Depot formulations
Hyaluronic acid	High viscosity	0.1–0.5%	Depot formulations

Excipient Compatibility Testing

Preformulation Studies

1. Solubility studies:

• Determine peptide solubility in various buffers
• Identify precipitation pH
• Assess ionic strength effects

2. Stability-indicating methods:

• HPLC for purity
• Mass spectrometry for degradation products
• Biological activity assays

3. Compatibility screening:

• Incubate peptide with individual excipients
• Monitor at 25°C/60% RH and 40°C/75% RH
• Duration: 2–4 weeks

Analytical Methods

1. Chromatographic methods:

• RP-HPLC: Purity, degradation products
• IEX-HPLC: Charge variants
• SEC-HPLC: Aggregates

2. Spectroscopic methods:

• UV-Vis: Concentration, aggregation
• Fluorescence: Conformational changes
• CD: Secondary structure

3. Physical methods:

• DSC: Thermal transitions
• Turbidity: Aggregation
• Particle counting: Particulates

Formulation Examples

Insulin Formulation

**Component	Concentration	Purpose**
Human insulin	100 IU/mL	Active ingredient
m-Cresol	0.25%	Preservative
Phenol	0.25%	Preservative
Zinc oxide	0.017 mg/mL	Stability
Glycerol	2.5%	Tonicity
Na₂HPO₄	1.6 mg/mL	Buffer

Semaglutide Formulation (Ozempic)

**Component	Concentration	Purpose**
Semaglutide	2–8 mg/mL	Active ingredient
Disodium phosphate dihydrate	1.42 mg/mL	Buffer
Propylene glycol	1.0%	Co-solvent
Phenol	5.5 mg/mL	Preservative
Hydrochloric acid	q.s.	pH adjustment

Liraglutide Formulation (Victoza)

**Component	Concentration	Purpose**
Liraglutide	6 mg/mL	Active ingredient
Propylene glycol	16.5 mg/mL	Co-solvent
Phenol	5.4 mg/mL	Preservative
Na₂HPO₄·2H₂O	1.4 mg/mL	Buffer
Water for injection	q.s.	Vehicle

Regulatory Considerations

Excipient Selection

1. Pharmacopeial status:

• USP/NF: Compendial excipients
• EP/JPE: European standards
• Non-compendial: Additional justification required

2. Safety data:

• ADME data for excipients
• Toxicology data
• Clinical experience

3. Regulatory filings:

• CTD Module 3: Quality
• Excipient information in drug substance and product sections

Compatibility with Container Closure

1. Glass vials:

• Type I borosilicate glass
• May leach ions affecting stability

2. Elastomeric stoppers:

• Silicone or butyl rubber
• May absorb excipients or peptides

3. Prefilled syringes:

• Silicone oil lubrication
• May affect aggregation

Summary

Peptide formulation excipients are critical for ensuring stability, isotonicity, and patient safety. Buffer selection should consider pH range, compatibility, and catalytic effects. Tonicity agents must match physiological osmolality without affecting stability. Stabilizers (antioxidants, surfactants, cryoprotectants) protect against degradation during storage and processing. Comprehensive compatibility testing is essential for excipient selection. The choice of excipients must balance efficacy, safety, and regulatory requirements.

Deep dive: Explore Peptide Formulation Development for detailed formulation protocols, or read about Peptide Lyophilization Optimization for freeze-drying considerations.

Test yourself: Take the Peptide Formulation Quiz or study with Formulation Excipient Flashcards.